Claims for Patent: 7,541,148
✉ Email this page to a colleague
Summary for Patent: 7,541,148
Title: | Method for detecting base mutation |
Abstract: | The present invention relates to methods for precisely and effectively detecting mutations of organism. |
Inventor(s): | Kim; Nam-Keun (Gyeonggi-do, KR), Kim; Suk-Joon (Seoul, KR), Kim; Soo-Ok (Seoul, KR), Kim; Eun-Ok (Seoul, KR), Moon; Myung-Soon (Seoul, KR), Yoo; Wang-Don (Gyeonggi-do, KR), Lee; Chang-Hong (Seoul, KR), Chung; Hyun-Jae (Gyeonggi-do, KR), Jee; Mi-Sun (Seoul, KR), Hwang; Seong-Gyu (Seoul, KR), Hong; Sun-Pyo (Seoul, KR) |
Assignee: | Genematrix, Inc. (Seoul, KR) |
Application Number: | 11/726,725 |
Patent Claims: | 1. A primer for analyzing a gene mutation comprising a primer binding sequence 1, a restriction enzyme recognition sequence and a primer binding sequence 2, wherein two or
more single stranded polynucleotide fragments that contain at least one mutation sequence respectively and have sizes of 2-32 bases are produced by amplifying with the primer and cleaving with two or more restriction enzymes recognizing the restriction
enzyme recognition sequence, and the primer is selected from the group consisting of SEQ ID NO: 2, 7, 12, 20, 25 and 30.
2. The primer according to claim 1, wherein the restriction enzymes have different optimum temperatures. 3. The primer according to claim 2, wherein a first restriction enzyme is Fok1 and a second restriction enzyme is BstF5. 4. The primer according to claim 1, wherein the primer is used for mutation analysis of the 2741.sup.ST or 3597.sup.TH base site of the 4.sup.TH intron of human maspin gene or for mutation analysis of lamivudine resistant hepatitis B virus or hepatitis C virus. |
Details for Patent 7,541,148
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2022-10-18 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2022-10-18 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2022-10-18 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.